By Memorandum Order entered by The Honorable Sue L. Robinson in Par Pharmaceutical, Inc., et al. v. Breckenridge Pharmaceutical, Inc., et al., Civil Action No. 15-486-SLR (D.Del., September 10, 2015), the Court denied the motion to transfer venue filed by defendants Twi Pharmaceuticals, Inc. and Twi Pharmaceuticals USA, Inc. after expressly disagreeing with defendants reasoning that the Court should transfer venue to the District of Maryland based on the fact that the Maryland court had previously rendered a decision on a related patent and after finding that neither the private nor the public factors identified in Jumara supported defendants' request for venue transfer.
A copy of the Memorandum Order is attached.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
[View Source]